Journal of Medicinal Chemistry · 2016 · 18 citations · 32 references
MedicineMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryNeuropharmacologyCholinergic PharmacologyDrug-receptor InteractionsHeterocyclic ChemistryLead Compound DesignLigand BindingReceptor PharmacologyCholinergic Receptor PharmacologyHeterocyclic Medicinal ChemistryMedicinal HeterocyclesNicotinic Receptor PharmacologyPartial Agonist EfficacyPartial Agonist PotencySelectivityStructure-based Ligand Design
The design and synthesis of a series of quinuclidine-containing spirooxazolidines (“spiroimidates”) and their utility as α7 nicotinic acetylcholine receptor partial agonists are described. Selected members of the series demonstrated excellent selectivity for α7 over the highly homologous 5-HT 3A receptor. Modification of the N -spiroimidate heterocycle substituent led to (1 S,2 R,4 S )- N -isoquinolin-3-yl)-4′ H -4-azaspiro[bicyclo[2.2.2]octane-2,5′oxazol]-2′-amine (BMS-902483), a potent α7 partial agonist, which improved cognition in preclinical rodent models.
32
Mihály Hajós, Raymond S Hurst, William E. Hoffmann et al. · Journal of Pharmacology and Experimental Therapeutics · 2005 · 223 citations
Donn G. Wishka, Daniel P. Walker, Karen M. Yates et al. · Journal of Medicinal Chemistry · 2006 · 190 citations · Full text